Article
From Genome to Drugs: New Approaches in Antimicrobial Discovery
Registro en:
SERRAL, Federico et al. From Genome to Drugs: New Approaches in Antimicrobial Discovery. Frontiers in Pharmacology, 2021.
1663-9812
10.3389/fphar.2021.647060
Autor
Serral, Federico
Castello, Florencia A.
Sosa, Ezequiel J.
Pardo, Agustín M.
Palumbo, Miranda Clara
Modenutti, Carlos
Palomino, María Mercedes
Lazarowski, Alberto
Auzmendi, Jerónimo
Ramos, Pablo Ivan P.
Nicolás, Marisa F.
Turjanski, Adrián G.
Martí, Marcelo A.
Porto, Darío Fernández do
Resumen
CNPq (process no. 306894/
2019-0) and granted by CAPES (process no. 88887.368759/ Decades of successful use of antibiotics is currently challenged by the emergence of
increasingly resistant bacterial strains. Novel drugs are urgently required but, in a scenario
where private investment in the development of new antimicrobials is declining, efforts to
combat drug-resistant infections become a worldwide public health problem. Reasons
behind unsuccessful new antimicrobial development projects range from inadequate
selection of the molecular targets to a lack of innovation. In this context, increasingly
available omics data for multiple pathogens has created new drug discovery and
development opportunities to fight infectious diseases. Identification of an appropriate
molecular target is currently accepted as a critical step of the drug discovery process.
Here, we review how diverse layers of multi-omics data in conjunction with structural/
functional analysis and systems biology can be used to prioritize the best candidate
proteins. Once the target is selected, virtual screening can be used as a robust
methodology to explore molecular scaffolds that could act as inhibitors, guiding the
development of new drug lead compounds. This review focuses on how the advent of
omics and the development and application of bioinformatics strategies conduct a “bigdata
era” that improves target selection and lead compound identification in a costeffective
and shortened timeline.